{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:50:19Z","timestamp":1791917419205,"version":"4.3.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2013,7,5]],"date-time":"2013-07-05T00:00:00Z","timestamp":1372982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Rivaroxaban (Xarelto, Bayer HealthCare, Leverkusen, Germany) is a new oral anticoagulant drug. Anticoagulants may cause bleeding, thereby requiring reliable monitoring and efficient therapy. We investigated thromboelastometry versus routine coagulation tests to measure prophylactic and therapeutic concentrations of rivaroxaban and their reversal with prothrombin complex concentrate (PCC) and activated recombinant factor VII (rFVIIa) in vitro.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Rivaroxaban was solubilized, and PCC and rFVIIa were added in 2 concentrations to the rivaroxaban-spiked blood samples, and thromboelastometry and measurements were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Rivaroxaban increased tissue factor\u2013activated clotting time (CT\n                      <jats:sub>ExTEM<\/jats:sub>\n                      ) dose dependently. Activated partial prothrombin time (aPTT), prothrombin time ratio (PTR), and prothrombin time (PT) were changed significantly in both concentrations. Reversal with PCC in both dosages caused no significant change in the measured parameters. For prophylactic rivaroxaban dosage, rFVIIa changed the PT significantly but not CT\n                      <jats:sub>ExTEM<\/jats:sub>\n                      , aPTT, and PTR. For therapeutic rivaroxaban dosage, the CT\n                      <jats:sub>ExTEM<\/jats:sub>\n                      was significantly reduced. The other parameters remained unaffected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Thromboelastometry can detect rivaroxaban effects. In vitro rFVIIa seems highly effective for reversal in contrast to PCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1076029613494468","type":"journal-article","created":{"date-parts":[[2013,7,5]],"date-time":"2013-07-05T20:57:12Z","timestamp":1373057832000},"page":"735-740","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":33,"title":["Measurement and Reversal of Prophylactic and Therapeutic Peak Levels of Rivaroxaban"],"prefix":"10.1177","volume":"20","author":[{"given":"Mareike Kristina","family":"K\u00f6rber","sequence":"first","affiliation":[{"name":"Department of Anesthesiology and Intensive Care Medicine, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Campus Virchow-Klinikum and Campus Charit\u00e9 Mitte, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Langer","sequence":"additional","affiliation":[{"name":"Labor Berlin\u2014Charite Vivantes, GmbH, Berlin, Germany"},{"name":"Institute for Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Campus Charit\u00e9 Mitte, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Ziemer","sequence":"additional","affiliation":[{"name":"Institute for Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Campus Charit\u00e9 Mitte, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Perzborn","sequence":"additional","affiliation":[{"name":"Bayer Healthcare AG, Wuppertal, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Gericke","sequence":"additional","affiliation":[{"name":"Institute of Medical Biometrics and Clinical Epidemiology, Charit\u00e9\u2013Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian von","family":"Heymann","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care Medicine, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Campus Virchow-Klinikum and Campus Charit\u00e9 Mitte, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2013,7,5]]},"reference":[{"key":"bibr1-1076029613494468","unstructured":"Medication guide for Xarelto\n                      \u00ae\n                      , FDA, ID 3053960"},{"key":"bibr2-1076029613494468","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.06.011"},{"key":"bibr3-1076029613494468","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181f2f264"},{"key":"bibr4-1076029613494468","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-06-0391"},{"key":"bibr5-1076029613494468","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-10-0667"},{"key":"bibr6-1076029613494468","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-011-0559-8"},{"issue":"1","key":"bibr7-1076029613494468","first-page":"A39","volume":"36","author":"Gruber A","year":"2007","journal-title":"Pathophysiol Haemos Thromb"},{"key":"bibr8-1076029613494468","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2007.09.002"},{"key":"bibr9-1076029613494468","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.029017"},{"key":"bibr10-1076029613494468","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e318238c036"},{"key":"bibr11-1076029613494468","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e318289bcba"},{"key":"bibr12-1076029613494468","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1270"},{"issue":"3","key":"bibr13-1076029613494468","first-page":"453","volume":"100","author":"Mueck W","year":"2008","journal-title":"Thromb Haemost"},{"key":"bibr14-1076029613494468","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.04152.x"},{"key":"bibr15-1076029613494468","unstructured":"Instructions for use of r ex-TEM\n                      \u00ae\n                      , TEM Innovations GmbH, Munich, Germany"},{"key":"bibr16-1076029613494468","doi-asserted-by":"publisher","DOI":"10.1097\/01.mbc.0000169225.31173.19"},{"key":"bibr17-1076029613494468","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-03-0176"},{"key":"bibr18-1076029613494468","doi-asserted-by":"publisher","DOI":"10.1007\/s00101-009-1623-z"},{"key":"bibr19-1076029613494468","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2012.03.029"},{"key":"bibr20-1076029613494468","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e318238c070"}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1076029613494468","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1076029613494468","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1076029613494468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:05:06Z","timestamp":1777385106000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1076029613494468"}},"subtitle":["An In Vitro Study"],"short-title":[],"issued":{"date-parts":[[2013,7,5]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.1177\/1076029613494468"],"URL":"https:\/\/doi.org\/10.1177\/1076029613494468","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,5]]}}}